Is NETTER-2 a practice-changing trial?

IF 81.1 1区医学 Q1 ONCOLOGY

Nature Reviews Clinical Oncology Pub Date : 2024-07-09 DOI:10.1038/s41571-024-00925-8

Jonathan Strosberg, Mauro Cives

引用次数: 0

Abstract

The NETTER-2 trial provides the first phase III evidence that 177Lu-dotatate is active as first-line therapy in patients with gastroenteropancreatic neuroendocrine tumours with a Ki-67 proliferative index of 10–55%. This approach is an important addition to the first-line therapeutic armamentarium, although treatment selection based on patient-specific and tumour-specific characteristics remains appropriate.

查看原文本刊更多论文

NETTER-2 是一项改变实践的试验吗？

NETTER-2试验首次提供了III期证据，证明177Lu-dotatate作为一线疗法对Ki-67增殖指数为10-55%的胃肠胰神经内分泌肿瘤患者有积极作用。这种方法是对一线治疗手段的重要补充，尽管根据患者特异性和肿瘤特异性特征选择治疗方法仍然是适当的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.

文献相关原料

公司名称	产品信息	采购帮参考价格